Qianjiang Yongan Pharmaceutical Co., Ltd.
002365.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.97B
Close$
$5.94
49.2% downside
Current Fair Value
49.2% downsideOvervalued by 49.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.97 Billion |
|---|---|
| Enterprise Value | $3.77 Billion |
| Dividend Yield | $0.10 (0.74%) |
| Earnings per Share | $0.08 |
| Beta | 0.29 |
| Outstanding Shares | 289,145,150 |
Return
| Return on Equity | 2.67% |
|---|---|
| Return on Assets | 2.40% |
| Return on Invested Capital | 3.25% |
Valuation & Multiples
| P/E Ratio | 74.3 |
|---|---|
| PEG | 66.61 |
| Price to Sales | 3.89 |
| Price to Book Ratio | 1.95 |
| Enterprise Value to Revenue | 3.85 |
| Enterprise Value to EBIT | 57.81 |
| Enterprise Value to Net Income | 70 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Qianjiang Yongan Pharmaceutical Co., Ltd.
912 employees
CEO: Ren Gui Hong Qianjiang Yongan Pharmaceutical Co., Ltd. engages in production and sale of taurine in China. It produces ethylene oxide, polycarboxylic acid-based water reducer monomers, water reducers, and health products. The company engages in scien...